The Indian market is expected to trade higher on January 15, supported by positive global cues. Nifty futures gained 0.51% on ...

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

The Nifty50 had a gap-up opening at 23,216.50 on Tuesday and ended the day at 23,176.05, up 0.39% from Monday's close.

Motilal Oswal (MOSL) has reiterated its "Buy" rating on HCL Technologies, setting a target price of Rs 2,400, which implies a ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the company, has received approval for ...